

# Jeanny B Aragon-Ching

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5608796/publications.pdf>

Version: 2024-02-01

152  
papers

4,257  
citations

172386

29  
h-index

118793

62  
g-index

153  
all docs

153  
docs citations

153  
times ranked

5952  
citing authors

| #  | ARTICLE                                                                                                                                                                                                                                                                                                 | IF    | CITATIONS |
|----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------|-----------|
| 1  | Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma. <i>New England Journal of Medicine</i> , 2020, 383, 1218-1230.                                                                                                                                                            | 13.9  | 802       |
| 2  | American Cancer Society prostate cancer survivorship care guidelines. <i>Ca-A Cancer Journal for Clinicians</i> , 2014, 64, 225-249.                                                                                                                                                                    | 157.7 | 324       |
| 3  | Clinical Cancer Advances 2017: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. <i>Journal of Clinical Oncology</i> , 2017, 35, 1341-1367.                                                                                                                      | 0.8   | 318       |
| 4  | Randomized Crossover Pharmacokinetic Study of Solvent-Based Paclitaxel and nab-Paclitaxel. <i>Clinical Cancer Research</i> , 2008, 14, 4200-4205.                                                                                                                                                       | 3.2   | 204       |
| 5  | A Phase II Clinical Trial of Sorafenib in Androgen-Independent Prostate Cancer. <i>Clinical Cancer Research</i> , 2008, 14, 209-214.                                                                                                                                                                    | 3.2   | 174       |
| 6  | Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial. <i>Lancet</i> , The, 2017, 390, 2266-2277.                                               | 6.3   | 153       |
| 7  | Hand-Foot Skin Reaction Increases with Cumulative Sorafenib Dose and with Combination Anti-Vascular Endothelial Growth Factor Therapy. <i>Clinical Cancer Research</i> , 2009, 15, 1411-1416.                                                                                                           | 3.2   | 135       |
| 8  | Impact of androgen-deprivation therapy on the immune system: implications for combination therapy of prostate cancer. <i>Frontiers in Bioscience - Landmark</i> , 2007, 12, 4957.                                                                                                                       | 3.0   | 130       |
| 9  | ABCB1 Genetic Variation Influences the Toxicity and Clinical Outcome of Patients with Androgen-Independent Prostate Cancer Treated with Docetaxel. <i>Clinical Cancer Research</i> , 2008, 14, 4543-4549.                                                                                               | 3.2   | 127       |
| 10 | Higher Incidence of Osteonecrosis of the Jaw (ONJ) in Patients with Metastatic Castration Resistant Prostate Cancer Treated with Anti-Angiogenic Agents. <i>Cancer Investigation</i> , 2009, 27, 221-226.                                                                                               | 0.6   | 115       |
| 11 | Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer. <i>BJU International</i> , 2009, 103, 1636-1640.                                                                                                                                                | 1.3   | 112       |
| 12 | CNS Metastasis: An Old Problem in a New Guise. <i>Clinical Cancer Research</i> , 2007, 13, 1644-1647.                                                                                                                                                                                                   | 3.2   | 89        |
| 13 | Role of chemotherapy in prostate cancer. <i>Asian Journal of Andrology</i> , 2018, 20, 221.                                                                                                                                                                                                             | 0.8   | 85        |
| 14 | Docetaxel As Monotherapy or Combined With Ramucirumab or Icrucumab in Second-Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma: An Open-Label, Three-Arm, Randomized Controlled Phase II Trial. <i>Journal of Clinical Oncology</i> , 2016, 34, 1500-1509.                         | 0.8   | 72        |
| 15 | Thalidomide Analogues as Anticancer Drugs. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , 2007, 2, 167-174.                                                                                                                                                                                      | 0.8   | 69        |
| 16 | Maintenance avelumab + best supportive care (BSC) versus BSC alone after platinum-based first-line (1L) chemotherapy in advanced urothelial carcinoma (UC): JAVELIN Bladder 100 phase III interim analysis.. <i>Journal of Clinical Oncology</i> , 2020, 38, LBA1-LBA1.                                 | 0.8   | 64        |
| 17 | Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 105-120. | 5.1   | 61        |
| 18 | VEGF Inhibitors and Prostate Cancer Therapy. <i>Current Molecular Pharmacology</i> , 2009, 2, 161-168.                                                                                                                                                                                                  | 0.7   | 59        |

| #  | ARTICLE                                                                                                                                                                                                                                           | IF  | CITATIONS |
|----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 19 | Vitamin D in prostate cancer. <i>Asian Journal of Andrology</i> , 2018, 20, 244.                                                                                                                                                                  | 0.8 | 59        |
| 20 | Phase I Study of Oral Lenalidomide in Patients With Refractory Metastatic Cancer. <i>Journal of Clinical Pharmacology</i> , 2009, 49, 650-660.                                                                                                    | 1.0 | 52        |
| 21 | A Double-Blind Randomized Crossover Study of Oral Thalidomide Versus Placebo for Androgen Dependent Prostate Cancer Treated With Intermittent Androgen Ablation. <i>Journal of Urology</i> , 2009, 181, 1104-1113.                                | 0.2 | 41        |
| 22 | Role of immunotherapy in bladder cancer. <i>Cancer Treatment and Research Communications</i> , 2021, 26, 100296.                                                                                                                                  | 0.7 | 41        |
| 23 | The changing landscape in the treatment of metastatic castration-resistant prostate cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2013, 5, 25-40.                                                                                     | 1.4 | 40        |
| 24 | Kinetics of Serum Androgen Normalization and Factors Associated With Testosterone Reserve After Limited Androgen Deprivation Therapy for Nonmetastatic Prostate Cancer. <i>Journal of Urology</i> , 2008, 180, 1432-1437.                         | 0.2 | 36        |
| 25 | Multidisciplinary Management of Muscle-Invasive Bladder Cancer: Current Challenges and Future Directions. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018, 38, 307-318. | 1.8 | 35        |
| 26 | Role of Chemotherapy and Mechanisms of Resistance to Chemotherapy in Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Medicine Insights: Oncology</i> , 2016, 10s1, CMO.S34535.                                                       | 0.6 | 34        |
| 27 | Characterization of Differences Between Prostate Cancer Patients Presenting With De Novo Versus Primary Progressive Metastatic Disease. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 85-89.                                                   | 0.9 | 34        |
| 28 | Bone-Targeted Therapies in Metastatic Castration-Resistant Prostate Cancer: Evolving Paradigms. <i>Prostate Cancer</i> , 2013, 2013, 1-10.                                                                                                        | 0.4 | 33        |
| 29 | The Role of Angiogenesis Inhibitors in Prostate Cancer. <i>Cancer Journal (Sudbury, Mass )</i> , 2008, 14, 20-25.                                                                                                                                 | 1.0 | 31        |
| 30 | The Current Landscape of Treatment in Non-Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Medicine Insights: Oncology</i> , 2019, 13, 117955491983392.                                                                               | 0.6 | 30        |
| 31 | The Evolution of Prostate Cancer Therapy: Targeting the Androgen Receptor. <i>Frontiers in Oncology</i> , 2014, 4, 295.                                                                                                                           | 1.3 | 28        |
| 32 | Angiogenesis Inhibition in Prostate Cancer: Current Uses and Future Promises. <i>Journal of Oncology</i> , 2010, 2010, 1-7.                                                                                                                       | 0.6 | 27        |
| 33 | Targeting Bone Metastases in Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Medicine Insights: Oncology</i> , 2016, 10, 11.                                                                                                         | 0.6 | 27        |
| 34 | Acute aortic dissection in a hypertensive patient with prostate cancer undergoing chemotherapy containing bevacizumab. <i>Acta Oncologica</i> , 2008, 47, 1600-1601.                                                                              | 0.8 | 24        |
| 35 | Phase II Study of Satraplatin and Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer: A Pharmacogenetic Assessment of Outcome and Toxicity. <i>Clinical Genitourinary Cancer</i> , 2013, 11, 229-237.                    | 0.9 | 23        |
| 36 | Zoledronic acid for the treatment of prostate cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 657-666.                                                                                                                               | 0.9 | 23        |

| #  | ARTICLE                                                                                                                                                                                                                                                                                              | IF  | CITATIONS |
|----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 37 | Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): Long-term follow-up results from the JAVELIN Bladder 100 trial.. Journal of Clinical Oncology, 2022, 40, 487-487.                                                                                                       | 0.8 | 23        |
| 38 | Anti-angiogenesis approach to genitourinary cancer treatment. Update on Cancer Therapeutics, 2009, 3, 182-188.                                                                                                                                                                                       | 0.9 | 22        |
| 39 | Metastatic Castration-Resistant Prostate Cancer: Critical Review of Enzalutamide. Clinical Medicine Insights: Oncology, 2013, 7, CMO.S11670.                                                                                                                                                         | 0.6 | 22        |
| 40 | From clinical trials to clinical practice: therapeutic cancer vaccines for the treatment of prostate cancer. Expert Review of Vaccines, 2011, 10, 743-753.                                                                                                                                           | 2.0 | 20        |
| 41 | Advances and Controversies With Checkpoint Inhibitors in Bladder Cancer. Clinical Medicine Insights: Oncology, 2021, 15, 117955492110449.                                                                                                                                                            | 0.6 | 18        |
| 42 | Unravelling the role of denosumab in prostate cancer. Lancet, The, 2011, 377, 785-786.                                                                                                                                                                                                               | 6.3 | 17        |
| 43 | Mucosa-Associated Lymphoma Tissue of the Dura Presenting as Meningioma. Southern Medical Journal, 2010, 103, 950-952.                                                                                                                                                                                | 0.3 | 15        |
| 44 | Treatment of Adult Soft Tissue Sarcoma: Old Concepts, New Insights, and Potential for Drug Discovery. Cancer Investigation, 2012, 30, 300-308.                                                                                                                                                       | 0.6 | 13        |
| 45 | Targeted therapies in the treatment of urothelial cancers. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 465-472.                                                                                                                                                               | 0.8 | 13        |
| 46 | Angiogenesis inhibitors in prostate cancer therapy. Discovery Medicine, 2010, 10, 521-30.                                                                                                                                                                                                            | 0.5 | 13        |
| 47 | Chemotherapy in Androgen-Independent Prostate Cancer (AIPC): What's next after taxane progression?. Cancer Therapy, 2007, 5A, 151-160.                                                                                                                                                               | 2.9 | 12        |
| 48 | Complete Response to EPOCH in a Patient With HIV and Extracavitary Primary Effusion Lymphoma Involving the Colon: A Case Report and Review of Literature. Clinical Lymphoma, Myeloma and Leukemia, 2012, 12, 144-147.                                                                                | 0.2 | 11        |
| 49 | Circulating Tumor Cells in Biochemical Recurrence of Prostate Cancer. Clinical Genitourinary Cancer, 2015, 13, e341-e345.                                                                                                                                                                            | 0.9 | 11        |
| 50 | A multicentre, international, randomised, open-label phase 3 trial of avelumab + best supportive care (BSC) vs BSC alone as maintenance therapy after first-line platinum-based chemotherapy in patients with advanced urothelial cancer (JAVELIN bladder 100). Annals of Oncology, 2016, 27, vi292. | 0.6 | 11        |
| 51 | Challenges and advances in the diagnosis, biology, and treatment of urothelial upper tract and bladder carcinomas. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 462-464.                                                                                                       | 0.8 | 11        |
| 52 | Radium-223 for the treatment of castration-resistant prostate cancer. OncoTargets and Therapy, 2015, 8, 1103.                                                                                                                                                                                        | 1.0 | 10        |
| 53 | The immunotherapy revolution in genitourinary malignancies. Immunotherapy, 2020, 12, 819-831.                                                                                                                                                                                                        | 1.0 | 10        |
| 54 | Advances with androgen deprivation therapy for prostate cancer. Expert Opinion on Pharmacotherapy, 2022, 23, 1015-1033.                                                                                                                                                                              | 0.9 | 10        |

| #  | ARTICLE                                                                                                                                                                                                                 | IF   | CITATIONS |
|----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-----------|
| 55 | Novel androgen deprivation therapy (ADT) in the treatment of advanced prostate cancer. <i>Drug Discovery Today: Therapeutic Strategies</i> , 2010, 7, 31-35.                                                            | 0.5  | 9         |
| 56 | A Contemporary Review of Immune Checkpoint Inhibitors in Advanced Clear Cell Renal Cell Carcinoma. <i>Vaccines</i> , 2021, 9, 919.                                                                                      | 2.1  | 9         |
| 57 | Osteonecrosis of the Jaw and the Use of Antiangiogenic Agents: Just an Association?. <i>Oncologist</i> , 2008, 13, 1314-1314.                                                                                           | 1.9  | 8         |
| 58 | Positron emission tomography findings in clinical mimics of lymphoma. <i>Annals of the New York Academy of Sciences</i> , 2011, 1228, 19-28.                                                                            | 1.8  | 8         |
| 59 | Primary Diffuse Large B-Cell Lymphoma of the Ureter in a Patient With HIV: A Case Report and Review of Literature. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, 324-326.                                  | 0.2  | 8         |
| 60 | Systemic therapy in muscle-invasive and metastatic bladder cancer: current trends and future promises. <i>Future Oncology</i> , 2016, 12, 2049-2058.                                                                    | 1.1  | 8         |
| 61 | Epithelioid Angiosarcoma of the Bladder: A Case Report and Review of the Literature. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e1091-e1095.                                                                      | 0.9  | 8         |
| 62 | Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): Analysis of clinical and genomic subgroups from the JAVELIN Bladder 100 trial.. <i>Journal of Clinical Oncology</i> , 2021, 39, 4520-4520. | 0.8  | 8         |
| 63 | Protein kinase inhibitors for the treatment of prostate cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 1889-1899.                                                                                         | 0.9  | 8         |
| 64 | A synopsis of drugs currently in preclinical and early clinical development for the treatment of benign prostatic hyperplasia. <i>Expert Opinion on Investigational Drugs</i> , 2015, 24, 1059-1073.                    | 1.9  | 7         |
| 65 | The promising role of nivolumab in renal cell cancers. <i>Cancer Biology and Therapy</i> , 2016, 17, 123-124.                                                                                                           | 1.5  | 7         |
| 66 | Carcinomas of the Renal Pelvis, Ureters, and Urinary Bladder Share a Carcinogenic Field as Revealed in Epidemiological Analysis of Tumor Registry Data. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 436-442.       | 0.9  | 7         |
| 67 | Frontline immunotherapy treatment with nivolumab and ipilimumab in metastatic renal cell cancer: a new standard of care. <i>Cancer Biology and Therapy</i> , 2019, 20, 6-7.                                             | 1.5  | 7         |
| 68 | The Potential Role for Immunotherapy in Biochemically Recurrent Prostate Cancer. <i>Urologic Clinics of North America</i> , 2020, 47, 457-467.                                                                          | 0.8  | 7         |
| 69 | The emerging role of prostate-specific membrane antigen (PSMA) PET-CT in patients with high-risk prostate cancer: moving the bar in high-risk prostate cancer. <i>Asian Journal of Andrology</i> , 2021, 23, 1.         | 0.8  | 7         |
| 70 | Reimbursement Policy and Androgen-Deprivation Therapy for Prostate Cancer. <i>New England Journal of Medicine</i> , 2011, 364, 579-580.                                                                                 | 13.9 | 6         |
| 71 | Use of Denosumab for Renal Cell Carcinoma-Associated Malignant Hypercalcemia: A Case Report and Review of the Literature. <i>Clinical Genitourinary Cancer</i> , 2013, 11, e24-e26.                                     | 0.9  | 6         |
| 72 | Advanced prostate cancer &ndash; patient survival and potential impact of enzalutamide and other emerging therapies. <i>Therapeutics and Clinical Risk Management</i> , 2014, 10, 651.                                  | 0.9  | 6         |

| #  | ARTICLE                                                                                                                                                                                                                                                                      | IF  | CITATIONS |
|----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 73 | Maintenance avelumab for metastatic urothelial cancer: a new standard of care. <i>Cancer Biology and Therapy</i> , 2020, 21, 1095-1096.                                                                                                                                      | 1.5 | 6         |
| 74 | Pembrolizumab use in bladder cancer: a tale of two trials. <i>Nature Reviews Urology</i> , 2021, 18, 577-578.                                                                                                                                                                | 1.9 | 6         |
| 75 | Carcinomas of the renal pelvis, ureters, and urinary bladder arise by similar carcinogenic pathways: A pathoepidemiological analysis.. <i>Journal of Clinical Oncology</i> , 2019, 37, 403-403.                                                                              | 0.8 | 6         |
| 76 | Active Surveillance for Prostate Cancer: Has the Time Finally Come?. <i>Journal of Clinical Oncology</i> , 2010, 28, e265-e266.                                                                                                                                              | 0.8 | 5         |
| 77 | Enzalutamide (formerly MDV3100) as a new therapeutic option for men with metastatic castration-resistant prostate cancer. <i>Asian Journal of Andrology</i> , 2012, 14, 805-806.                                                                                             | 0.8 | 5         |
| 78 | Ipilimumab. <i>Cancer Biology and Therapy</i> , 2014, 15, 1299-1300.                                                                                                                                                                                                         | 1.5 | 5         |
| 79 | New Developments and Challenges in Rare Genitourinary Tumors: Non-Urothelial Bladder Cancers and Squamous Cell Cancers of the Penis. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 330-336. | 1.8 | 5         |
| 80 | New Developments and Challenges in Rare Genitourinary Tumors: Non-Urothelial Bladder Cancers and Squamous Cell Cancers of the Penis. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 330-336. | 1.8 | 5         |
| 81 | Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: Are We Asking the Right Questions?. <i>Journal of Clinical Oncology</i> , 2014, 32, 4169-4170.                                                                                                                  | 0.8 | 4         |
| 82 | Advances in systemic therapies for metastatic castration-resistant prostate cancer. <i>Future Oncology</i> , 2014, 10, 2213-2226.                                                                                                                                            | 1.1 | 4         |
| 83 | Osteonecrosis of the jaw (ONJ) in androgen-independent prostate cancer (AIPC) patients receiving ATTP (bevacizumab, docetaxel, thalidomide, and prednisone). <i>Journal of Clinical Oncology</i> , 2007, 25, 19594-19594.                                                    | 0.8 | 4         |
| 84 | Differences in survival among non-urothelial bladder cancers: Analyses of SEER 1988-2008.. <i>Journal of Clinical Oncology</i> , 2018, 36, 425-425.                                                                                                                          | 0.8 | 4         |
| 85 | Darolutamide for treatment of castration-resistant prostate cancer. <i>Drugs of Today</i> , 2020, 56, 185.                                                                                                                                                                   | 0.7 | 4         |
| 86 | Darolutamide: a novel androgen-signaling agent in nonmetastatic castration-resistant prostate cancer. <i>Asian Journal of Andrology</i> , 2020, 22, 76.                                                                                                                      | 0.8 | 4         |
| 87 | Further analysis of the survival benefit of clodronate. <i>Cancer Biology and Therapy</i> , 2009, 8, 2219-2220.                                                                                                                                                              | 1.5 | 3         |
| 88 | About tyrosine kinase inhibitors (TKIs) in prostate cancer: where do we go from here?. <i>Annals of Oncology</i> , 2010, 21, 183-184.                                                                                                                                        | 0.6 | 3         |
| 89 | 2508 Three-arm phase II randomized trial of docetaxel monotherapy or combined with ramucirumab or icrucumab in second-line locally advanced or metastatic urothelial carcinoma. <i>European Journal of Cancer</i> , 2015, 51, S476.                                          | 1.3 | 3         |
| 90 | Targeting Bone Metastases in Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Medicine Insights: Oncology</i> , 2016, 10s1, CMO.Ss30751.                                                                                                                         | 0.6 | 3         |

| #   | ARTICLE                                                                                                                                                                                                              | IF  | CITATIONS |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 91  | Impact of abiraterone on patient-related outcomes in metastatic castration-resistant prostate cancer: current perspectives. <i>Cancer Management and Research</i> , 2017, Volume 9, 299-306.                         | 0.9 | 3         |
| 92  | Formidable Scenarios in Urothelial and Variant Cancers of the Urinary Tract. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, 262-275. | 1.8 | 3         |
| 93  | Treatment in hormone-sensitive metastatic prostate cancer: factors to consider when personalizing therapy. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 483-490.                                           | 1.1 | 3         |
| 94  | Plasmacytoid Variant of Urothelial Carcinoma: Poor Prognostic Variant with High Expression of CDH1 Mutation. <i>Uro</i> , 2021, 1, 23-29.                                                                            | 0.3 | 3         |
| 95  | Darolutamide (DARO) tolerability from extended follow up and treatment response in the phase 3 ARAMIS trial.. <i>Journal of Clinical Oncology</i> , 2021, 39, 5079-5079.                                             | 0.8 | 3         |
| 96  | Molecular profiling of aggressive variant urothelial carcinoma.. <i>Journal of Clinical Oncology</i> , 2019, 37, 378-378.                                                                                            | 0.8 | 3         |
| 97  | The Utility of Chemotherapy in the Treatment of Metastatic Prostate Cancer. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2016, 16, 1166-1171.                                                                  | 0.9 | 3         |
| 98  | The path forward in prostate cancer therapeutics. <i>Asian Journal of Andrology</i> , 2018, 20, 213.                                                                                                                 | 0.8 | 3         |
| 99  | Predictive biomarkers for survival benefit with ramucirumab in urothelial cancer in the RANGE trial. <i>Nature Communications</i> , 2022, 13, 1878.                                                                  | 5.8 | 3         |
| 100 | Editorial [Hot topic: Prostate Cancer Therapy (Guest Editors: N. Sharifi and J.B. Aragon-Ching)]. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2009, 9, 1039-1039.                                             | 0.9 | 2         |
| 101 | Cytotoxic Compounds in the Treatment of Castration-Resistant Prostate Cancer. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2009, 9, 1040-1045.                                                                 | 0.9 | 2         |
| 102 | Is there an optimal treatment sequencing strategy for metastatic castration-resistant prostate cancer?. <i>Future Oncology</i> , 2013, 9, 619-622.                                                                   | 1.1 | 2         |
| 103 | Further analysis of PREVAIL: Enzalutamide use in chemotherapy-naïve men with metastatic castration-resistant prostate cancer. <i>Asian Journal of Andrology</i> , 2014, 16, 803.                                     | 0.8 | 2         |
| 104 | Mucinous Signet-Ring Urachal Carcinoma of the Bladder: Case Report and Review of the Literature. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e889-e891.                                                         | 0.9 | 2         |
| 105 | Promises and Pitfalls of Primary Local Treatment in Metastatic Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 914-914.                                                                             | 0.8 | 2         |
| 106 | Adjuvant Chemotherapy for High-Risk Localized Prostate Cancer: Time for Change or Need More Time to Change?. <i>Journal of Clinical Oncology</i> , 2019, 37, 2296-2297.                                              | 0.8 | 2         |
| 107 | The Clinical Utility of Bevacizumab. , 2008, , 375-385.                                                                                                                                                              |     | 2         |
| 108 | Comparative analyses of trends and survival in patients with urothelial versus nonurothelial bladder carcinoma: National Cancer Database (NCDB) analysis.. <i>Journal of Clinical Oncology</i> , 2019, 37, 402-402.  | 0.8 | 2         |

| #   | ARTICLE                                                                                                                                                                                                                                          | IF  | CITATIONS |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 109 | The promising role of poly(ADP-ribose) polymerase inhibitors in prostate cancer. <i>Asian Journal of Andrology</i> , 2016, 18, 592.                                                                                                              | 0.8 | 2         |
| 110 | Characterization of differences between prostate cancer (PCa) patients presenting as de novo versus primary progressive metastatic disease.. <i>Journal of Clinical Oncology</i> , 2015, 33, 285-285.                                            | 0.8 | 2         |
| 111 | Non-urothelial bladder cancer: Genomic alterations and patient outcomes.. <i>Journal of Clinical Oncology</i> , 2019, 37, 399-399.                                                                                                               | 0.8 | 2         |
| 112 | Cardiovascular Disease With Androgen Deprivation: The (forgotten) Role of Testosterone. <i>Journal of Clinical Oncology</i> , 2009, 27, e261-e261.                                                                                               | 0.8 | 1         |
| 113 | Editorial [Hot Topic: Multidrug Resistance: Genes, Polymorphisms, Biologic Effects, Reversal and Treatment in Cancer Chemotherapy (Guest Editor: Jeanny B. Aragon-Ching)]. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2010, 10, 582-582. | 0.9 | 1         |
| 114 | The use of 5-alpha-reductase inhibitors for the prevention of prostate cancer. <i>Cancer Biology and Therapy</i> , 2010, 10, 11-12.                                                                                                              | 1.5 | 1         |
| 115 | Mechanisms of Drug Resistance to Vascular Endothelial Growth Factor (VEGF) Inhibitors. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2010, 10, 593-600.                                                                                     | 0.9 | 1         |
| 116 | Hematuria in sickle cell trait: the importance of ruling out occult cancer. <i>Annals of Hematology</i> , 2012, 91, 137-138.                                                                                                                     | 0.8 | 1         |
| 117 | Targeting the androgen receptor in metastatic castration-resistant prostate cancer. <i>Future Oncology</i> , 2014, 10, 329-332.                                                                                                                  | 1.1 | 1         |
| 118 | Drug therapies for metastatic castration-resistant prostate cancer. <i>Future Oncology</i> , 2015, 11, 2395-2403.                                                                                                                                | 1.1 | 1         |
| 119 | The Emerging Role of Combination Angiogenesis Inhibitors and Immune Checkpoint Inhibitors in the Treatment of Metastatic Renal Cell Cancer. <i>Kidney Cancer</i> , 2019, 3, 81-91.                                                               | 0.2 | 1         |
| 120 | Life under the CABOSUN: Cabozantinib improves quality-adjusted survival in comparison with sunitinib. <i>Cancer</i> , 2020, 126, 5210-5212.                                                                                                      | 2.0 | 1         |
| 121 | Characterization of Brain Metastases in Urothelial Cancers. <i>Clinical Genitourinary Cancer</i> , 2020, 18, e679-e683.                                                                                                                          | 0.9 | 1         |
| 122 | Balancing efficacy and quality of life measurements among metastatic renal cell carcinoma (RCC) studies. <i>Oncoscience</i> , 2021, 8, 40-45.                                                                                                    | 0.9 | 1         |
| 123 | Implications for chemoprevention of prostate cancer with intake of cruciferous vegetables. <i>Asian Journal of Andrology</i> , 2011, 13, 357-358.                                                                                                | 0.8 | 1         |
| 124 | Circulating tumor cells (CTCs) in biochemical recurrence (BR) of prostate cancer: Final results.. <i>Journal of Clinical Oncology</i> , 2013, 31, 179-179.                                                                                       | 0.8 | 1         |
| 125 | A phase I/II trial of ketoconazole + calcitriol [1,25(OH)2D3] in castration-resistant prostate cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 5065-5065.                                                                               | 0.8 | 1         |
| 126 | Retrospective review of clear cell and non-clear cell renal carcinomas: Characteristics and course in the pre-TKI (tyrosine kinase inhibitor) and post-TKI era.. <i>Journal of Clinical Oncology</i> , 2017, 35, e16052-e16052.                  | 0.8 | 1         |



| #   | ARTICLE                                                                                                                                                                                                                                   | IF  | CITATIONS |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 127 | Treatment utilization patterns for prostate cancer (PCa): An analysis from the National Cancer Database (NCDB).. Journal of Clinical Oncology, 2017, 35, 99-99.                                                                           | 0.8 | 1         |
| 128 | Enzalutamide: a new indication for nonmetastatic castration-resistant prostate cancer. Asian Journal of Andrology, 2019, 21, 107.                                                                                                         | 0.8 | 1         |
| 129 | Investigational Angiogenesis Inhibitors. , 2010, , 225-232.                                                                                                                                                                               |     | 1         |
| 130 | Bevacizumab and Angiogenesis Inhibitors in the Treatment of CNS Metastases: The Road less Travelled. Current Molecular Pharmacology, 2013, 5, 382-391.                                                                                    | 0.7 | 1         |
| 131 | Contemporary treatment and survival differences in patients with urothelial versus nonurothelial bladder and upper tract carcinomas: Analyses from the National Cancer Database (NCDB).. Journal of Clinical Oncology, 2022, 40, 463-463. | 0.8 | 1         |
| 132 | Lack of prognostic significance of prostate biopsies in metastatic androgen independent prostate cancer. BJU International, 2007, 100, 1245-1248.                                                                                         | 1.3 | 0         |
| 133 | Reply. Clinical Cancer Research, 2009, 15, 7749-7749.                                                                                                                                                                                     | 3.2 | 0         |
| 134 | New Pharmacotherapies in the Treatment of Advanced Prostate Cancer. Clinical Medicine Insights Urology, 2010, 4, CMU.S5075.                                                                                                               | 0.4 | 0         |
| 135 | Circulating Tumor Cells. , 2014, 19, 229-233.                                                                                                                                                                                             |     | 0         |
| 136 | Use of early chemotherapy for hormone-sensitive prostate cancer: time for CHARTED. Asian Journal of Andrology, 2016, 18, 444.                                                                                                             | 0.8 | 0         |
| 137 | Key Difficulties Associated with Cancer Biology. Clinical Medicine Insights: Oncology, 2016, 10s1, CMO.S41271.                                                                                                                            | 0.6 | 0         |
| 138 | The emerging role of checkpoint inhibitors for rare genitourinary cancers. Nature Reviews Urology, 2021, 18, 133-134.                                                                                                                     | 1.9 | 0         |
| 139 | Comparative analyses of survival differences in patients with urothelial versus non-urothelial upper tract carcinomas: Results from the National Cancer Database (NCDB).. Journal of Clinical Oncology, 2021, 39, e16582-e16582.          | 0.8 | 0         |
| 140 | MP41-13â€fAVELUMAB FIRST-LINE MAINTENANCE FOR ADVANCED UROTHELIAL CARCINOMA: ANALYSIS OF CLINICAL AND GENOMIC SUBGROUPS FROM THE JAVELIN BLADDER 100 TRIAL. Journal of Urology, 2021, 206, .                                              | 0.2 | 0         |
| 141 | PD40-11â€fCLINICAL ACTIVITY OF NIVOLUMAB IN ADVANCED HEREDITARY LEIOMYOMATOSIS AND RENAL CELL CANCER (HLRCC)-ASSOCIATED KIDNEY CANCER. Journal of Urology, 2021, 206, .                                                                   | 0.2 | 0         |
| 142 | Exploratory covariate analysis for phase II clinical trial of sorafenib (S) in metastatic castrate-resistant prostate cancer (mCRPC). Journal of Clinical Oncology, 2008, 26, 14690-14690.                                                | 0.8 | 0         |
| 143 | Circulating tumor cells (CTCs) as a predictor of metastatic disease in patients with biochemical recurrence (BR) of prostate cancer with equivocal scan results.. Journal of Clinical Oncology, 2012, 30, 239-239.                        | 0.8 | 0         |
| 144 | Pilot study assessing distressors affecting patients with cancer using the distress screening tool.. Journal of Clinical Oncology, 2015, 33, 68-68.                                                                                       | 0.8 | 0         |

| #   | ARTICLE                                                                                                                                                                                                                                                                                                                                   | IF  | CITATIONS |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 145 | Effects of PSA screening guidelines on trends of diagnosis and treatment for prostate cancer: Analysis from the National Cancer Data Base (NCDB).. Journal of Clinical Oncology, 2016, 34, 74-74.                                                                                                                                         | 0.8 | 0         |
| 146 | Incidence and characterization of pure non-urothelial bladder and upper tract cancers: A 10-year review.. Journal of Clinical Oncology, 2016, 34, 414-414.                                                                                                                                                                                | 0.8 | 0         |
| 147 | Survival outcomes for de novo versus primary progressive metastatic prostate cancer.. Journal of Clinical Oncology, 2017, 35, 258-258.                                                                                                                                                                                                    | 0.8 | 0         |
| 148 | Survival outcomes and patterns of utilization of cytoreductive nephrectomy in the tyrosine kinase inhibitors (TKI)-era in metastatic clear cell renal cell carcinoma (ccRCC) and non-clear cell renal cell carcinoma (nccRCC): Analyses from the National Cancer Database (NCDB).. Journal of Clinical Oncology, 2017, 35, e16068-e16068. | 0.8 | 0         |
| 149 | Molecular characterization of brain metastases in patients with metastatic urothelial cancer.. Journal of Clinical Oncology, 2018, 36, 509-509.                                                                                                                                                                                           | 0.8 | 0         |
| 150 | Pilot Study Assessing Distressors Affecting Patients with Cancer Using the Distress Thermometer Screening Tool. Hematology & Medical Oncology, 2020, 5, .                                                                                                                                                                                 | 0.1 | 0         |
| 151 | Bevacizumab and Angiogenesis Inhibitors in the Treatment of CNS metastases: the Road less Travelled. Current Molecular Pharmacology, 2013, , .                                                                                                                                                                                            | 0.7 | 0         |
| 152 | Rapidly evolving first-line therapy using checkpoint inhibitors in metastatic renal cell cancer. Future Medicinal Chemistry, 2022, , .                                                                                                                                                                                                    | 1.1 | 0         |